|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 199.36 USD | +0.71% |
|
+5.41% | +13.28% |
| 05-12 | Roche gets second European approval for Alzheimer's test | RE |
| 05-08 | Biogen Says FDA Extends Priority Review Period for Leqembi Iqlik by 3 Months | MT |
| Capitalization | 29.43B 25.1B 23.02B 21.79B 40.39B 2,817B 40.77B 274B 107B 1,336B 110B 108B 4,643B | P/E ratio 2026 * |
32.2x | P/E ratio 2027 * | 16.7x |
|---|---|---|---|---|---|
| Enterprise value | 35.02B 29.87B 27.4B 25.93B 48.06B 3,352B 48.52B 326B 127B 1,590B 131B 129B 5,525B | EV / Sales 2026 * |
3.5x | EV / Sales 2027 * | 3.2x |
| Free-Float |
85.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Biogen Inc.
| 1 day | +0.71% | ||
| 1 week | +5.41% | ||
| Current month | +5.33% | ||
| 1 month | +15.26% | ||
| 3 months | +1.97% | ||
| 6 months | +23.46% | ||
| Current year | +13.28% |
| 1 week | 188.86 |  | 202.4 |
| 1 month | 174.85 | | 202.4 |
| Current year | 160.36 | | 202.41 |
| 1 year | 119.18 | | 202.41 |
| 3 years | 110.04 | | 319.76 |
| 5 years | 110.04 | | 468.55 |
| 10 years | 110.04 | | 468.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 2022-11-13 | |
Robin Kramer
DFI | Director of Finance/CFO | 60 | 2025-02-28 |
Guy Hadari
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Caroline Dorsa
CHM | Chairman | 66 | 2023-06-25 |
Eric Rowinsky
BRD | Director/Board Member | 69 | 2010-03-22 |
Stephen Sherwin
BRD | Director/Board Member | 77 | 2009-12-31 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | -.--% | 1.69% | 2 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.71% | +5.41% | +60.26% | -35.61% | 29.43B | |
| +1.49% | +3.01% | +25.67% | -2.81% | 73.6B | |
| -1.20% | +0.97% | +52.12% | +175.87% | 53.86B | |
| -1.03% | +44.30% | +44.30% | +44.30% | 44.71B | |
| +0.24% | -20.71% | -58.97% | -67.91% | 34.53B | |
| +0.74% | +14.04% | +107.28% | -58.80% | 21.14B | |
| -1.19% | +1.70% | +62.91% | +51.85% | 19.8B | |
| -1.86% | -3.92% | +74.10% | +117.35% | 19.66B | |
| -0.14% | -0.54% | +45.52% | +84.60% | 16.3B | |
| +1.96% | -4.11% | +84.84% | +386.90% | 12.92B | |
| Average | -0.20% | -0.12% | +49.80% | +69.57% | 32.59B | |
| Weighted average by Cap. | -0.09% | +0.05% | +40.57% | +50.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10.01B 8.54B 7.83B 7.41B 13.74B 958B 13.87B 93.27B 36.32B 455B 37.57B 36.78B 1,579B | 10.32B 8.8B 8.07B 7.64B 14.16B 987B 14.29B 96.11B 37.43B 468B 38.71B 37.9B 1,627B |
| Net income | 1.12B 957M 877M 831M 1.54B 107B 1.55B 10.45B 4.07B 50.93B 4.21B 4.12B 177B | 1.95B 1.66B 1.52B 1.44B 2.68B 187B 2.7B 18.16B 7.07B 88.51B 7.32B 7.16B 308B |
| Net Debt | 5.59B 4.77B 4.37B 4.14B 7.67B 535B 7.75B 52.1B 20.29B 254B 20.98B 20.54B 882B | 3.62B 3.08B 2.83B 2.68B 4.96B 346B 5.01B 33.69B 13.12B 164B 13.57B 13.28B 570B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-05-12 | 199.36 $ | +0.71% | 1,145,749 |
| 26-05-11 | 197.95 $ | +2.33% | 1,772,229 |
| 26-05-08 | 193.45 $ | +1.08% | 931,578 |
| 26-05-07 | 191.38 $ | +0.37% | 735,692 |
| 26-05-06 | 190.68 $ | +0.82% | 741,346 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BIIB Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition